MISSISSAUGA, ON, May 27, 2011 /CNW/ - Mr. Brian Pedlar, President and
CEO of Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:
COV), an advanced medical technologies company, is pleased to provide
the following update.
Covalon has expanded its sales, business development and marketing
initiatives with the addition of five experienced medical industry
sales, business development and marketing staff, the redeployment of
internal staff to sales and marketing roles and the introduction of new
wound care products and medical coating formulations for license and
distribution. The focus of the entire staff is on developing new
business opportunities for the Company's core wound care products and
medical coating services. In addition, the Company is also working on
the introduction of promising new technologies and formulations for
Covalon's existing channel and direct to consumers. The Company
announced financial results for its second quarter ended March 31,
2011. Quarterly revenue was $1,011,436. Quarterly operating expenses
were $1,139,577. Net loss was $430,610 or $0.006 per share. Covalon
continues to have a strong balance sheet with no debt and $3,931,454 in
cash, cash equivalents and short-term investments as of March 31, 2011.
Dr. Val DiTizio, Covalon's Chief Scientific Officer and co-founder said,
"Covalon is a different company today than it was a year ago. Our
talented scientific team is working in a coordinated fashion with the
new business development team in ways that did not occur in the past.
We have a number of new developments that I am extremely excited about
and should prove to be of serious interest to both medical device
companies and direct consumers."
Mr. Brian Pedlar, Covalon's President and Chief Executive Officer
stated, "I am proud of the progress we have made and am extremely
optimistic about the Company's technologies and future prospects."
Covalon Technologies Ltd. is a unique medical technologies company
engaged in the research, development, and commercialization of advanced
tissue repair applications, infection control, and specialized coatings
for medical and consumer products. Together, our technology platforms,
wound care products, and consulting services deliver a suite of
cost-effective solutions to help our customers achieve product
differentiation through improved patient outcomes. Our technologies
address important healthcare issues such as infection control, medical
device biocompatibility and healthy tissue repair. To learn more about
Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will",
"should", "could" or "might" occur or be achieved and other similar
expressions. These forward-looking statements involve risk and
uncertainties, including the difficulty in predicting product
approvals, acceptance of and demands for new products, the impact of
the products and pricing strategies of competitors, delays in
developing and launching new products, the regulatory environment,
fluctuations in operating results and other risks, any of which could
cause results, performance, or achievements to differ materially from
the results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific to
the Company. Investors should consult the Company's ongoing quarterly
filings for additional information on risks and uncertainties relating
to these forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements whether as
a result of new information, further events or otherwise.
SOURCE Covalon Technologies Ltd.
For further information:
CEO, Covalon Technologies Ltd.
T: (905) 568-8400 x 233
F: (905) 568-5200